Search CommunityWalk:


OncoImmunin, Inc.

207A Perry Parkway, Suite 6
Gaithersburg, MD, USA

Category: Drug Delivery

Used in the following map:

Maryland Biotech Industry Map

OncoImmunin, Inc. is a biotechnology company that has designed, synthesized, validated and patented a new class of molecules that can serve as fluorogenic protease substrates for enzymatic activity determinations in live cells as well as in serum, in vivo delivery vehicles for oligonucleotides. It was founded in 1994 by Akira Komoriya and Beverly Packard.

OncoImmunin's fluorogenic protease substrate design allows determination of intracellular enzymatic activity using a fluorescence microscope. Determination of activity in buffer solution as well as in human serum can be accomplished using a standard fluorometer, or for large sample throughput, a proprietary high-throughput screening (HTS) system is available.

OncoImmunin's new class of cell permeable fluorogenic protease substrates are PhiPhiLux® is a novel and unique class of fluorogenic apoptosis assay substrates for the detection and measurement of caspase 3 and caspase 3-like activities in living cells, CyToxiLux®, PanToxiLux(TM) and GranToxiLux® is useful to measure cell death exclusively in target cell populations by flow cytometry or fluorescence microscopy, etc.

OncoImmunin has been issued three U.S. patents and one Australian patent on its proprietary design for protease inhibitors and fluorogenic substrates.